Less than 20%...versus a sugar pill. When 12% of the patients cannot tolerate a 30mg sugar pill versus 14% not being able to tolerate 30mg drug...well that shows that the drug is amazingly well tolerated. Compare that, for example, to the 50% of Daybue drug patients who actually stopped taking the drug because of side effects (diarrhea and vomiting.) Very, VERY impressive.
We have a winner and I appreciate the opportunities that you and doc and investor give me to underscore this for other investors who read this board. Thanks.
but efficacy suffers when 1/3 patients are not on targeted dose
It's been shown that patients with favorable genetics (i.e. WT) experience efficacy at much smaller doses; therefore, patients who couldn't be up-titrated were likely those experiencing efficacy at lower doses.
All that means is there would be less patients in the higher dose arm and more in the lower. 88% reached their target; that's significant.
This is likely the reason that the AD TLD used aggregate calculations. Missling stated that there was little difference in efficacy between 30mg and 50mg. 30mg (and lower for some) is efficacious for many.
Market Data 
Markets 
AI
